Cargando…
An Evaluation of the Immunohistochemical Expression of Mismatch Repair Proteins (MSH2, MSH6, MLH1, and PMS2) in Prostate Adenocarcinoma
Background and objective Mismatch repair (MMR) proteins are an integral part of the cell cycle, and they play an important role in the genomic stability of the microsatellite complex. Microsatellite instability (MSI) is associated with Lynch and multi-tumor syndromes. Identifying patients with Lynch...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9420449/ https://www.ncbi.nlm.nih.gov/pubmed/36051725 http://dx.doi.org/10.7759/cureus.27448 |
_version_ | 1784777392410066944 |
---|---|
author | Javeed, Saira Chughtai, Anila Zafar, Ghazi Khalid, Fatima Batool, Ayma Chughtai, Akhtar S |
author_facet | Javeed, Saira Chughtai, Anila Zafar, Ghazi Khalid, Fatima Batool, Ayma Chughtai, Akhtar S |
author_sort | Javeed, Saira |
collection | PubMed |
description | Background and objective Mismatch repair (MMR) proteins are an integral part of the cell cycle, and they play an important role in the genomic stability of the microsatellite complex. Microsatellite instability (MSI) is associated with Lynch and multi-tumor syndromes. Identifying patients with Lynch syndrome is essential for screening, early detection, and surveillance of other Lynch syndrome-associated tumors. The role of MMR deficiency is well known in colorectal and endometrial adenocarcinoma. However, the role of MMR deficiency in prostatic adenocarcinoma is a matter of controversy. A few studies have been published to analyze the association between MMR deficiency and prostatic adenocarcinoma. In this study, we used immunohistochemistry to look into the expression of four MMR proteins in prostatic adenocarcinoma: MSH2, MSH6, MLH1, and PMS2. Methodology This was a cross-sectional descriptive study involving 74 cases of acinar prostatic adenocarcinoma, diagnosed with hematoxylin & eosin (H&E), over a period of six months between December 2021 and May 2022 at the Chughtai Institute of Pathology in Lahore, Pakistan. We performed the immunohistochemical (IHC) analysis and interpretation of four antibodies, i.e., MSH2, MSH6, MLH1, and PMS2. Results In our study, the age of the patients ranged from 50 to 98 years, with a mean age of 67.99 ± 9.59 years. The specimens were collected through transurethral resection of the prostate (TURP), transurethral vaporization of the prostate (TVP), core biopsy, and radical prostatectomy. Isolated loss of each MSH2 and PMS2 was noted in nine cases (12.20%) and MSH6 in two cases (2.70%). There was no loss noted for MLH1. Furthermore, simultaneous loss of MSH2/MSH6 was observed in one case (1.35%). Conclusion Our study findings revealed a low frequency of IHC expression of MMR proteins, especially the concurrent loss of paired MMR proteins. However, prostatic adenocarcinoma is associated with the isolated loss of MMR proteins. Thus, the present study does not warrant reflex testing/screening in every case of prostatic adenocarcinoma, because of its low frequency, which is probably suggestive of its sporadic pattern. |
format | Online Article Text |
id | pubmed-9420449 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-94204492022-08-31 An Evaluation of the Immunohistochemical Expression of Mismatch Repair Proteins (MSH2, MSH6, MLH1, and PMS2) in Prostate Adenocarcinoma Javeed, Saira Chughtai, Anila Zafar, Ghazi Khalid, Fatima Batool, Ayma Chughtai, Akhtar S Cureus Pathology Background and objective Mismatch repair (MMR) proteins are an integral part of the cell cycle, and they play an important role in the genomic stability of the microsatellite complex. Microsatellite instability (MSI) is associated with Lynch and multi-tumor syndromes. Identifying patients with Lynch syndrome is essential for screening, early detection, and surveillance of other Lynch syndrome-associated tumors. The role of MMR deficiency is well known in colorectal and endometrial adenocarcinoma. However, the role of MMR deficiency in prostatic adenocarcinoma is a matter of controversy. A few studies have been published to analyze the association between MMR deficiency and prostatic adenocarcinoma. In this study, we used immunohistochemistry to look into the expression of four MMR proteins in prostatic adenocarcinoma: MSH2, MSH6, MLH1, and PMS2. Methodology This was a cross-sectional descriptive study involving 74 cases of acinar prostatic adenocarcinoma, diagnosed with hematoxylin & eosin (H&E), over a period of six months between December 2021 and May 2022 at the Chughtai Institute of Pathology in Lahore, Pakistan. We performed the immunohistochemical (IHC) analysis and interpretation of four antibodies, i.e., MSH2, MSH6, MLH1, and PMS2. Results In our study, the age of the patients ranged from 50 to 98 years, with a mean age of 67.99 ± 9.59 years. The specimens were collected through transurethral resection of the prostate (TURP), transurethral vaporization of the prostate (TVP), core biopsy, and radical prostatectomy. Isolated loss of each MSH2 and PMS2 was noted in nine cases (12.20%) and MSH6 in two cases (2.70%). There was no loss noted for MLH1. Furthermore, simultaneous loss of MSH2/MSH6 was observed in one case (1.35%). Conclusion Our study findings revealed a low frequency of IHC expression of MMR proteins, especially the concurrent loss of paired MMR proteins. However, prostatic adenocarcinoma is associated with the isolated loss of MMR proteins. Thus, the present study does not warrant reflex testing/screening in every case of prostatic adenocarcinoma, because of its low frequency, which is probably suggestive of its sporadic pattern. Cureus 2022-07-29 /pmc/articles/PMC9420449/ /pubmed/36051725 http://dx.doi.org/10.7759/cureus.27448 Text en Copyright © 2022, Javeed et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Pathology Javeed, Saira Chughtai, Anila Zafar, Ghazi Khalid, Fatima Batool, Ayma Chughtai, Akhtar S An Evaluation of the Immunohistochemical Expression of Mismatch Repair Proteins (MSH2, MSH6, MLH1, and PMS2) in Prostate Adenocarcinoma |
title | An Evaluation of the Immunohistochemical Expression of Mismatch Repair Proteins (MSH2, MSH6, MLH1, and PMS2) in Prostate Adenocarcinoma |
title_full | An Evaluation of the Immunohistochemical Expression of Mismatch Repair Proteins (MSH2, MSH6, MLH1, and PMS2) in Prostate Adenocarcinoma |
title_fullStr | An Evaluation of the Immunohistochemical Expression of Mismatch Repair Proteins (MSH2, MSH6, MLH1, and PMS2) in Prostate Adenocarcinoma |
title_full_unstemmed | An Evaluation of the Immunohistochemical Expression of Mismatch Repair Proteins (MSH2, MSH6, MLH1, and PMS2) in Prostate Adenocarcinoma |
title_short | An Evaluation of the Immunohistochemical Expression of Mismatch Repair Proteins (MSH2, MSH6, MLH1, and PMS2) in Prostate Adenocarcinoma |
title_sort | evaluation of the immunohistochemical expression of mismatch repair proteins (msh2, msh6, mlh1, and pms2) in prostate adenocarcinoma |
topic | Pathology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9420449/ https://www.ncbi.nlm.nih.gov/pubmed/36051725 http://dx.doi.org/10.7759/cureus.27448 |
work_keys_str_mv | AT javeedsaira anevaluationoftheimmunohistochemicalexpressionofmismatchrepairproteinsmsh2msh6mlh1andpms2inprostateadenocarcinoma AT chughtaianila anevaluationoftheimmunohistochemicalexpressionofmismatchrepairproteinsmsh2msh6mlh1andpms2inprostateadenocarcinoma AT zafarghazi anevaluationoftheimmunohistochemicalexpressionofmismatchrepairproteinsmsh2msh6mlh1andpms2inprostateadenocarcinoma AT khalidfatima anevaluationoftheimmunohistochemicalexpressionofmismatchrepairproteinsmsh2msh6mlh1andpms2inprostateadenocarcinoma AT batoolayma anevaluationoftheimmunohistochemicalexpressionofmismatchrepairproteinsmsh2msh6mlh1andpms2inprostateadenocarcinoma AT chughtaiakhtars anevaluationoftheimmunohistochemicalexpressionofmismatchrepairproteinsmsh2msh6mlh1andpms2inprostateadenocarcinoma AT javeedsaira evaluationoftheimmunohistochemicalexpressionofmismatchrepairproteinsmsh2msh6mlh1andpms2inprostateadenocarcinoma AT chughtaianila evaluationoftheimmunohistochemicalexpressionofmismatchrepairproteinsmsh2msh6mlh1andpms2inprostateadenocarcinoma AT zafarghazi evaluationoftheimmunohistochemicalexpressionofmismatchrepairproteinsmsh2msh6mlh1andpms2inprostateadenocarcinoma AT khalidfatima evaluationoftheimmunohistochemicalexpressionofmismatchrepairproteinsmsh2msh6mlh1andpms2inprostateadenocarcinoma AT batoolayma evaluationoftheimmunohistochemicalexpressionofmismatchrepairproteinsmsh2msh6mlh1andpms2inprostateadenocarcinoma AT chughtaiakhtars evaluationoftheimmunohistochemicalexpressionofmismatchrepairproteinsmsh2msh6mlh1andpms2inprostateadenocarcinoma |